BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29074329)

  • 1. Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes.
    Min SH; Oh TJ; Baek SI; Lee DH; Kim KM; Moon JH; Choi SH; Park KS; Jang HC; Lim S
    Diabetes Metab; 2018 Feb; 44(1):73-76. PubMed ID: 29074329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report.
    Yeo SM; Park H; Paek JH; Park WY; Han S; Park SB; Jin K
    Medicine (Baltimore); 2019 Jan; 98(3):e14150. PubMed ID: 30653152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
    Herring RA; Shojaee-Moradie F; Garesse R; Stevenage M; Jackson N; Fielding BA; Mendis A; Johnsen S; Umpleby AM; Davies M; Russell-Jones DL
    Diabetes Care; 2020 Sep; 43(9):2128-2136. PubMed ID: 32641376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
    Pfützner A; Klonoff D; Heinemann L; Ejskjaer N; Pickup J
    Endocrine; 2017 Apr; 56(1):212-216. PubMed ID: 28303514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
    Abdul-Ghani M; Migahid O; Megahed A; Singh R; Fawaz M; DeFronzo RA; Jayyousi A
    Diabetes Obes Metab; 2019 Mar; 21(3):705-709. PubMed ID: 30259621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report].
    Pereyra A M; Ramírez C; Román R
    Rev Chil Pediatr; 2017 Jun; 88(3):404-410. PubMed ID: 28737202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
    Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
    Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis.
    Wallenius K; Kroon T; Hagstedt T; Löfgren L; Sörhede-Winzell M; Boucher J; Lindén D; Oakes ND
    J Lipid Res; 2022 Mar; 63(3):100176. PubMed ID: 35120993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
    Lindberg MJ; Kristensen FB; Yildiz A
    Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
    Davis PN; Ndefo UA; Oliver A
    J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
    Demaris KM; White JR
    Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
    Henry RR; Dandona P; Pettus J; Mudaliar S; Xu J; Hansen L
    Diabetes Obes Metab; 2017 Jun; 19(6):814-821. PubMed ID: 28098426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
    Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
    Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
    Daniele G; Xiong J; Solis-Herrera C; Merovci A; Eldor R; Tripathy D; DeFronzo RA; Norton L; Abdul-Ghani M
    Diabetes Care; 2016 Nov; 39(11):2036-2041. PubMed ID: 27561923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study.
    Biester T; Muller I; von dem Berge T; Atlas E; Nimri R; Phillip M; Battelino T; Bratina N; Dovc K; Scheerer MF; Kordonouri O; Danne T
    Diabetes Obes Metab; 2021 Feb; 23(2):599-608. PubMed ID: 33217117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
    Kuhadiya ND; Ghanim H; Mehta A; Garg M; Khan S; Hejna J; Torre B; Makdissi A; Chaudhuri A; Batra M; Dandona P
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3506-15. PubMed ID: 27490915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin-Associated Diabetic Ketoacidosis.
    Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
    Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit.
    Thong KY; Yadagiri M; Barnes DJ; Morris DS; Chowdhury TA; Chuah LL; Robinson AM; Bain SC; Adamson KA; Ryder REJ;
    Prim Care Diabetes; 2018 Feb; 12(1):45-50. PubMed ID: 28669625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.